Physician profile
Judd B Adelman
NPI 1912940131
$67,243.94
in general payments reported to CMS, 2019-2025
40 companies · $37K in 2025
The $37K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $848 · 2021: $2,059 · 2022: $2,130 · 2023: $2,712 · 2024: $21K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $46K · Food and Beverage: $8,788 · Travel and Lodging: $6,702 · Education: $39.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,675.00 |
| Food and Beverage | $8,787.77 |
| Travel and Lodging | $6,701.98 |
| Education | $39.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $52,701.74 | 2024-2025 | Neptune, Pedi-Pom, Triton Canister System |
| Abbvie INC. | $3,348.20 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,554.88 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,448.32 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $1,447.31 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $629.11 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $542.03 | 2019-2025 | Entyvio, Eohilia |
| Nestle Healthcare Nutrition INC. | $517.46 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $338.86 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $338.79 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $316.28 | 2019-2024 | Dificid |
| Celltrion USA INC. | $285.40 | 2024-2025 | Zymfentra, Vegzelma |
| Madrigal Pharmaceuticals | $253.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $238.69 | 2021-2025 | Interstim |
| Daiichi Sankyo INC. | $230.26 | 2019-2024 | Injectafer |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $221.60 | 2019-2025 | |
| Celgene Corporation | $195.35 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $186.19 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $175.77 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $174.00 | 2019-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $168.33 | 2019-2024 | Rebyota, Clenpiq |
| Organon LLC | $165.92 | 2023-2025 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $165.12 | 2024-2025 | Zenpep |
| Genzyme Corporation | $115.30 | 2022-2024 | |
| Redhill Biopharma INC. | $106.99 | 2020-2022 | |
| Neuraxis, INC. | $58.37 | 2025 | |
| Boston Scientific Corporation | $38.69 | 2024-2025 | Cre Pro, Hydra Jagwire |
| Allergan, INC. | $38.54 | 2019-2020 | |
| Enterra Medical, INC. | $35.83 | 2022-2023 | |
| Alfasigma USA, INC. | $32.48 | 2020 | |
| Lilly USA, LLC | $31.19 | 2025 | Omvoh |
| Novo Nordisk INC | $29.69 | 2025 | Wegovy |
| Ethicon US, LLC | $21.26 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.65 | 2025 | Sutab |
| Capsovision, INC. | $16.08 | 2024 | Capsocam Plus |
| Echosens North America, INC. | $15.12 | 2023 | Fibroscan |
| Shionogi INC | $13.30 | 2019 | |
| Gilead Sciences, INC. | $12.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.80 | 2019 | |
| Romark Laboratories, Lc | $5.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judd Adelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.